MDAISpectral AI Inc. Class A Common Stock

Moby summary of Spectral AI, Inc.'s Q2 2026 earnings call

Spectral AI (NASDAQ:MDAI) said its second-quarter results marked a transition toward commercial operations following the U.S. Food and Drug Administration’s De Novo clearance of its DeepView System for burn assessment in May. The company reiterated its 2026 revenue guidance of approximately $18.5 mi

Spectral AI Inc (MDAI) outlines promising FDA submissions and strategic funding, despite facing revenue and cash flow hurdles.

Spectral AI (NASDAQ:MDAI) said it remains on track toward potential U.S. regulatory clearance and commercialization of its DeepView system for burn assessment, while reporting lower first-quarter research and development revenue tied to the completion of work under a federal contract. On the compan

Moby summary of Spectral AI, Inc.'s Q4 2025 earnings call

Before we begin, I'd like to remind everyone that during this call, certain statements made are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the company's strategy, plans, objectives, initiatives and financial outlook. When used in this call, the words estimates, projected, expects, anticipates, forecasts, plans, intends, believes, seeks, may, will, should, future, propose and variations of these words or similar expressions or the negative versions of such words or expressions are intended to identify forward-looking statements. As such, listeners are cautioned not to place undue reliance on any forward-looking statements.

Spectral AI Inc (MDAI) reports a significant reduction in net loss and strong cash position, while preparing for commercialization amidst revenue challenges.

Spectral AI (NASDAQ:MDAI) executives said fiscal 2025 marked a “pivotal year” as the company advanced its DeepView burn diagnostic system toward potential FDA clearance and strengthened its funding profile, highlighted by a new award under its longstanding BARDA partnership. DeepView FDA path and c

Key Insights Using the 2 Stage Free Cash Flow to Equity, Spectral AI fair value estimate is US$2.15 Spectral AI is...

Spectral AI Inc (MDAI) reports significant milestones and challenges in Q3 2025, with a focus on FDA approval and international market expansion.